GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant
Starts undertaking quality evaluation and characterization of iPSCs in accordance with ISO standards
PALO ALTO, Calif., Dec. 6, 2023 — Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that its Palo Alto quality control testing facility has been accredited as ISO 17025: 2017 compliant. The accreditation was certified by ANSI National Accreditation Board, one of the leading accreditation bodies in the world. The tests in the scope of accreditation center on the characterization of iPSCs and include cell count and viability per USP <1046>, detection of pluripotency marker expression by flow cytometry per USP <1027>, and also by immunofluorescence assay. [Read more…]
Exploring Alternative Treatments for Alleviating Pain from Osteoarthritis
As the years pass, our bodies take on many changes. Some we can control and others, like Osteoarthritis (OA), are a little more out of our hands – but that doesn’t mean you have to let it control you! In this article, we will explore the connection between aging and OA, what causes it, how to manage your symptoms effectively so that you can age gracefully with an active lifestyle. So if you’re ready to get proactive about your health as you age and learn how to best manage the effects of osteoarthritis in your life, then stay tuned for some exciting tips. [Read more…]
Pricing Of Approved Cell Therapy Products
Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T therapy in the United States. Novartis announced that its genetically modified autologous (“self-derived”) immunocellular therapy, Kymriah, will cost $475,000 per treatment course. Shortly thereafter, Kite Pharma announced the approval of its CAR-T therapy, Yescarta, in the U.S. with a list price of $373,000. While these prices are expensive, they are far from trendsetting.
Cell Therapy Pricing and Products
In this article:
StemSight Bolsters Leadership Team and Adds Extensive Experience in Cell Therapy Commercialization with Key Hire
In the field of groundbreaking regenerative medicine, StemSight’s aim to cure blindness takes a major leap forward with the strategic appointment of Dr Ross Macdonald as Chief Commercial Officer.
Tampere, Finland, 21.11.23 — StemSight Oy, the leading deep tech company dedicated to eliminating corneal blindness through stem cell technology, proudly announces the appointment of Dr Ross Macdonald to advance the Company’s commercial strategy. With over three decades of pharmaceutical and biopharma industry expertise, Macdonald’s inclusion in StemSight’s team brings a new breadth of experience to the Company. [Read more…]
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 201
- Next Page »